Step 1 topics → Respiratory → Asthma

Asthma

Asthma is a chronic inflammatory airway disease driven by Th2-mediated immune responses, characterized by reversible bronchoconstriction, mucus hypersecretion, and airway remodeling — and USMLE Step 1 hits it from multiple angles. The classic triad is episodic wheezing, cough, and dyspnea, but what makes it testable is the mechanism behind it and how you confirm the diagnosis. Expect pure recall of pathology findings, mechanism-based questions about cytokine roles, clinical vignettes distinguishing asthma from COPD, and diagnostic criteria that trip up nearly everyone who hasn't studied spirometry carefully.

The trickiest part is that asthma is not just 'obstruction on PFTs.' A low FEV1/FVC alone doesn't diagnose asthma — reversibility is the key criterion, and students who skip that step get burned on vignettes. There's also real confusion about the classic sputum findings (Curschmann spirals and Charcot-Leyden crystals), which many students incorrectly assign to COPD. And Samter triad shows up frequently because it tests both mechanism and management in a single question stem.

On USMLE Step 1, asthma questions often embed the diagnosis or mechanism in a longer clinical passage — a patient with nasal polyps and aspirin sensitivity, or a child with nocturnal cough and a spirometry result. You need to recognize the pattern, know what drives it immunologically, and know what the biopsy or sputum would show. The cytokine details (IL-4, IL-5, IL-13) are tested specifically, not just 'Th2 involvement' in general.

From real student decks
92%have cards covering this topic
73%have mature cards

Well-covered in most decks — the challenge is retention, not exposure.

Common misconceptions

Common mistake
Gap: Missing the specific Th2 cytokines (IL-4, IL-5, IL-13) and their roles in asthma pathogenesis
Asthma pathogenesis is driven by Th2 cytokines: IL-4 and IL-13 promote IgE class switching, IL-5 recruits eosinophils, and IL-4/IL-13 also drive mucus hypersecretion and airway remodeling.
Saying 'Th2 drives asthma' is not enough — the exam expects you to know which cytokines do what. IL-4 and IL-13 both drive IgE class switching in B cells and stimulate goblet cell hyperplasia and mucus production; IL-5 is the eosinophil cytokine, promoting their maturation, recruitment, and survival in the airway. Over time, IL-13 in particular drives subepithelial fibrosis and smooth muscle hypertrophy — that's airway remodeling. Knowing these roles lets you answer questions about targeted biologics (like mepolizumab targeting IL-5) and explains why eosinophilia and elevated IgE are expected findings.
Common mistake
Wrong: Curschmann spirals and Charcot-Leyden crystals are found in COPD sputum.
Right: Curschmann spirals (mucus plugs) and Charcot-Leyden crystals (eosinophil membrane protein) are classic sputum findings in asthma, not COPD.
This is a classic sputum-pathology mix-up. Curschmann spirals are mucus casts shed from small airways — they reflect the mucus plugging that defines asthma pathology, not emphysema or chronic bronchitis. Charcot-Leyden crystals form from the breakdown of eosinophil membranes (specifically galectin-10 protein), and since eosinophilic inflammation is the hallmark of allergic asthma, these crystals belong to asthma. COPD is driven by neutrophilic inflammation and smoking-related damage — you won't see eosinophil crystals or mucus plugs with the same character there.
Common mistake
Wrong: Samter triad patients can safely use COX-2 selective inhibitors because the reaction is to aspirin specifically.
Right: Samter triad (AERD) is caused by COX-1 inhibition shunting arachidonic acid to leukotrienes; COX-2 selective inhibitors are generally safe, but the reaction is a class effect of COX-1 inhibitors, not aspirin-specific.
The mechanism matters here: Samter triad (AERD) is caused by inhibition of COX-1, which normally converts arachidonic acid to prostaglandins including PGE2, a bronchodilator. When COX-1 is blocked by aspirin or traditional NSAIDs, arachidonic acid gets shunted into the 5-lipoxygenase pathway, massively increasing leukotriene production (LTC4, LTD4, LTE4), triggering bronchoconstriction. COX-2 selective inhibitors (celecoxib) spare COX-1 and don't cause this shunting, so they're generally safe in AERD. The practical takeaway: the reaction is a COX-1 class effect, not an aspirin-specific allergy, which is why all non-selective NSAIDs are problematic.
Common mistake
Wrong: Asthma is diagnosed when FEV1/FVC is reduced on spirometry.
Right: Asthma diagnosis requires demonstration of reversible airflow obstruction: ≥12% and ≥200 mL improvement in FEV1 after bronchodilator, or positive methacholine challenge.
An obstructive pattern on spirometry (FEV1/FVC < 0.70) appears in both asthma and COPD — finding obstruction alone does not make the diagnosis. What distinguishes asthma is that the obstruction is reversible: after giving a short-acting bronchodilator, FEV1 must improve by at least 12% AND at least 200 mL in absolute volume. If symptoms are present but spirometry is normal, a methacholine challenge can provoke bronchoconstriction and confirm airway hyperreactivity. Missing the reversibility criterion is the most common diagnostic error students make on Step 1 asthma questions.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Know the specific Th2 cytokines driving asthma — IL-4 and IL-13 promote IgE class switching and mucus production, IL-5 recruits and activates eosinophils — and how they together cause airway remodeling over time.
  2. Identify Curschmann spirals (shed mucus plugs) and Charcot-Leyden crystals (eosinophil membrane protein breakdown products) as sputum findings classic for asthma, and distinguish them from what you'd see in COPD.
  3. Recognize the asthma symptom pattern — episodic, often nocturnal or exercise-triggered, with expiratory wheezing — and identify signs of severe exacerbation including pulsus paradoxus, inability to speak, silent chest, and status asthmaticus.
  4. Apply the correct diagnostic criteria: an obstructive pattern on spirometry is not enough — you need ≥12% AND ≥200 mL improvement in FEV1 post-bronchodilator, or a positive methacholine challenge (bronchoconstriction in response to a cholinergic agent) to confirm reversibility.
  5. Identify Samter triad (aspirin-exacerbated respiratory disease) as the combination of asthma, nasal polyps, and aspirin/NSAID sensitivity, explain it via COX-1 inhibition shunting arachidonic acid toward leukotriene synthesis, and know that COX-2 selective inhibitors are generally safe while leukotriene receptor antagonists (e.g., montelukast) are the preferred treatment.

Can you avoid these mistakes?

A 19-year-old with seasonal allergies presents with episodic wheezing and cough. Spirometry shows FEV1/FVC of 0.65. After albuterol, FEV1 increases by 15% and 220 mL. What is the diagnosis, and what additional finding on sputum exam would support the underlying inflammatory mechanism?
A 35-year-old woman with asthma and nasal polyps develops acute bronchospasm after taking ibuprofen for a headache. What is the pathophysiologic mechanism, and why would celecoxib be a safer alternative for her pain management?
On a pathology slide of bronchial biopsy from a patient with chronic asthma, you see subepithelial fibrosis, smooth muscle hypertrophy, and goblet cell hyperplasia. Which specific Th2 cytokines drove each of these structural changes?
A patient with known asthma presents with severe dyspnea. On exam, you note a silent chest (no wheezing audible) and pulsus paradoxus of 18 mmHg. Why does absence of wheezing here indicate a more severe — not milder — exacerbation, and what is this condition called?

Related topics

PFT Patterns — Obstructive vs Restrictive Lung Development Stages Surfactant Production and Neonatal RDS Bronchopulmonary Dysplasia Congenital Diaphragmatic Hernia

See how your Anki deck covers this topic.

Upload your deck for a free audit →